GlassScriptPhysician profile
Fannie W Su
NPI 1982738712
$14,164.27
in general payments reported to CMS, 2019-2025
37 companies · $3,460 in 2025
The $3,460 reported for 2025 was more than what 79% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,440 · 2020: $947 · 2021: $1,466 · 2022: $1,686 · 2023: $2,085 · 2024: $3,080 · 2025: $3,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,600 · Consulting Fee: $913 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,599.57 |
| Consulting Fee | $913.36 |
| Education | $112.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,474.70 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,426.03 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,877.83 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,619.74 | 2019-2025 | Dupixent |
| Amgen INC. | $793.95 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $671.09 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Kaleo, INC. | $444.97 | 2019-2024 | Auvi-Q |
| Alk-Abello, INC | $410.92 | 2019-2025 | Odactra, Grastek |
| Teva Pharmaceuticals USA, INC. | $343.13 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $306.28 | 2019-2025 | |
| Optinose US, INC. | $290.16 | 2019-2025 | |
| Csl Behring | $285.70 | 2020-2025 | Hizentra, Haegarda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.53 | 2019-2021 | |
| Greer Laboratories, INC. | $224.92 | 2019-2025 | Oralair, Palforzia |
| Ars Pharmaceuticals Operations, INC. | $203.11 | 2025 | Neffy |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $184.70 | 2019-2023 | |
| Covis Pharma Gmbh | $146.45 | 2020-2022 | |
| Lilly USA, LLC | $141.10 | 2025 | Ebglyss, Taltz |
| Incyte Corporation | $122.42 | 2022-2024 | Opzelura |
| Galderma Laboratories, L.P. | $93.80 | 2025 | Nemluvio |
| Pharming Healthcare, INC. | $93.46 | 2020-2025 | Ruconest |
| Sanofi-Aventis U.S. LLC | $87.26 | 2019-2024 | |
| Grifols USA, LLC | $67.18 | 2025 | Xembify |
| Leo Pharma INC. | $66.31 | 2023-2025 | Adbry, Anzupgo |
| Phadia US INC. | $65.66 | 2022-2024 | Immunocap |
| Eyevance Pharmaceuticals LLC | $58.58 | 2021 | |
| Octapharma USA, INC. | $51.89 | 2023 | Cutaquig |
| Genentech USA, INC. | $50.37 | 2022-2024 | Xolair |
| Abbvie INC. | $48.49 | 2022 | |
| Biocryst US Sales Co., LLC | $42.03 | 2022-2025 | Orladeyo |
| Ionis Pharmaceuticals, INC. | $39.09 | 2025 | Dawnzera |
| Blueprint Medicines Corporation | $36.74 | 2024 | Ayvakit |
| Insmed, INC. | $36.19 | 2025 | Brinsupri, Arikayce |
| Shire North American Group INC | $33.77 | 2019 | |
| Adma Biomanufacturing LLC | $33.36 | 2024 | |
| Biocryst Pharmaceuticals, INC. | $20.36 | 2020 | |
| Uswm, LLC | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fannie Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.